Ladenburg also acts as Exclusive Advisor for In-License of Phase 3 Ready Asset, eRapa for Familial Adenomatous Polyposis (FAP)
Transaction Information
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced $6.5 million of gross proceeds from the exercise of previously issued warrants and an agreement between the Company and several accredited investors to exercise certain existing Series E and Series F warrants.
Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the warrant exercise transaction.
Biodexa Enters Into Exclusive License to eRapa™
Biodexa entered into a definitive agreement with Rapamycin Holdings Inc. (d/b/a Emtora Biosciences) ("Emtora") for the rights to eRapa, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP), under an exclusive, worldwide license (with the ability to grant sublicenses) to develop, manufacture, commercialize and otherwise advance the clinical potential of eRapa.
Ladenburg Thalmann & Co. Inc. acted as financial advisor to BioDexa in connection with this transaction.
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non Muscle Invasive Blader Cancer: tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. For more information visit www.biodexapharma.com
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.